Taylor PC, et al. - Researchers analyzed data from phase II and III baricitinib studies performed in rheumatoid arthritis (RA) patients, in order to determine the impact of statin therapy on lipid levels in patients on statins at baseline and in patients who initiated statins during the study. Results demonstrated the relationship of baricitinib with increased levels total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides. However, no significant change was seen in the LDL-C:HDL-C ratio. Those receiving statin therapy during the study, suggested a decrease in LDL-C, triglycerides and apolipoprotein B to pre-baricitinib levels, whereas HDL-C and apolipoprotein A-I levels remained increased.